TrialSite News Research Contributes to Indian Physicians Call for Ivermectin-based Research Targeting COVID-19

TrialSite News Research Contributes to Indian Physicians Call for Ivermectin-based Research Targeting COVID-19

According to a brief mention in the Times of India, a recent white paper discussing the potential of Ivermectin as a treatment for SARS-CoV-2 has been embraced by the World Health Organization (WHO). Published in the Indian Journal of Tuberculosis Elsevier, the recent article suggests WHO has referred to this literature. TrialSite News’ research efforts are recognized and cited, something that other journalists and media are failing to do too often. Indian physicians, including Dr. VK Aroroa (Delhi), Dr. D Behera (Chandigarh), Dr. Agam Vora (Mumbai), Dr. T Mohan Kumar (Coimbatore), Dr. Narayana Pradeep and Prof Surya Kant authored, “White Paper on Ivermectin as a Potential Therapy for COVID-19” in July, 2020.

The gathering of senior doctors with extensive clinical experience met on July 19, 2020 under the aegis of Academy of Advanced Medical Education. With Ivermectin as a focal point of discussion, the panel reviewed the growing off-label use of the common anti-parasitic drug targeting COVID-19. The group concluded that Ivermectin can be a potential molecule for prophylaxis and treatment of people infected with Coronavirus, due to its anti-viral properties, coupled with effective cost, availability and good tolerability and safety.

WHO Website

The recent Times of India piece declared that this discussion, led by Prof Surya Kant, made its way to WHO’s website. TrialSite analysts searched for such evidence and unfortunately couldn’t find it on the WHO website but perhaps there is some regional portal WHO operates.

TrialSite News Credit

TrialSite News is the leading media platform dedicated to clinical research chronicling the use of ivermectin and other therapies worldwide during the pandemic. A number of publications, websites and various authors have improperly copied or used research published by TrialSite without the standard citation or mention. Perhaps they mistakenly think it’s just some obscure website? TrialSite is grateful to Prof Surya Kant from King George Medical University and colleagues for the citations.

Lead Research/Investigator

Prof. Surya Kant, King George Medical University

Call to Action: Check out the White Paper on Ivermectin as a Potential Therapy for COVID-19